Search

Your search keyword '"Doorduijn, Jeanette"' showing total 494 results
Start Over Author "Doorduijn, Jeanette"
494 results on '"Doorduijn, Jeanette"'

2. Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

Author

de Groot, Fleur A., Dekker, Tim J.A., Doorduijn, Jeanette K., Böhringer, Stefan, Brink, Mirian, de Groen, Ruben A.L., de Haan, Lorraine M., Woei-A-Jin, F.J. Sherida H., Noordenbos, Troy, Sijs-Szabo, Aniko, Oudshoorn, Mirjam A., Lam, King H., Diepstra, Arjan, te Boome, Liane C.J., Terpstra, Valeska, Bohmer, Lara H., Nicolae, Alina, Posthuma, Eduardus F.M., Koens, Lianne, Durian, Marc F., Stavast, Jeroen, van der Poel, Marjolein W.M., Hamid, Myrurgia Abdul, Stevens, Wendy B.C., van Rooij, Sjo L.M., Oostvogels, Rimke S., Mühlebner, Angelika, Neelis, Karen J., van den Brand, Michiel, Tousseyn, Thomas, Dierickx, Daan, de Weerdt, Okke, Beeker, Aart, Jansen, Patty M., Kersten, Marie José, Zijlstra, Josée M., Chamuleau, Martine E.D., Veelken, Hendrik, Bromberg, Jacoline C.E., Nijland, Marcel, and Vermaat, Joost S.P.

Published
2024
Full Text
View/download PDF

4. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Author

Dreyling, Martin, Doorduijn, Jeanette, Giné, Eva, Jerkeman, Mats, Walewski, Jan, Hutchings, Martin, Mey, Ulrich, Riise, Jon, Trneny, Marek, Vergote, Vibeke, Shpilberg, Ofer, Gomes da Silva, Maria, Leppä, Sirpa, Jiang, Linmiao, Stilgenbauer, Stephan, Kerkhoff, Andrea, Jachimowicz, Ron D, Celli, Melania, Hess, Georg, Arcaini, Luca, Visco, Carlo, van Meerten, Tom, Wirths, Stefan, Zinzani, Pier Luigi, Novak, Urban, Herhaus, Peter, Benedetti, Fabio, Sonnevi, Kristina, Hanoun, Christine, Hänel, Matthias, Dierlamm, Judith, Pott, Christiane, Klapper, Wolfram, Gözel, Döndü, Schmidt, Christian, Unterhalt, Michael, Ladetto, Marco, and Hoster, Eva

Published
2024
Full Text
View/download PDF

5. MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

Author

Ferreri, Andrés J M, Doorduijn, Jeanette K, Re, Alessandro, Cabras, Maria Giuseppina, Smith, Jeffery, Ilariucci, Fiorella, Luppi, Mario, Calimeri, Teresa, Cattaneo, Chiara, Khwaja, Jahanzaib, Botto, Barbara, Cellini, Claudia, Nassi, Luca, Linton, Kim, McKay, Pam, Olivieri, Jacopo, Patti, Caterina, Re, Francesca, Fanni, Alessandro, Singh, Vikram, Bromberg, Jacoline E C, Cozens, Kelly, Gastaldi, Elisabetta, Bernardi, Massimo, Cascavilla, Nicola, Davies, Andrew, Fox, Christopher P, Frezzato, Maurizio, Osborne, Wendy, Liberati, Anna Marina, Novak, Urban, Zambello, Renato, Zucca, Emanuele, and Cwynarski, Kate

Published
2021
Full Text
View/download PDF

6. Primary central nervous system lymphomas:EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

Ferreri, Andreas J.M., Illerhaus, Gerald, Doorduijn, Jeanette K., Auer, Dorothee P., Bromberg, Jacoline E.C., Calimeri, Teresa, Cwynarski, Kate, Fox, Christopher P., Hoang-Xuan, Khê, Malaise, Denis, Ponzoni, Maurilio, Schorb, Elisabeth, Soussain, Carole, Specht, Lena, Zucca, Emanuele, Buske, Christian, Jerkeman, Mats, Dreyling, Martin, Ferreri, Andreas J.M., Illerhaus, Gerald, Doorduijn, Jeanette K., Auer, Dorothee P., Bromberg, Jacoline E.C., Calimeri, Teresa, Cwynarski, Kate, Fox, Christopher P., Hoang-Xuan, Khê, Malaise, Denis, Ponzoni, Maurilio, Schorb, Elisabeth, Soussain, Carole, Specht, Lena, Zucca, Emanuele, Buske, Christian, Jerkeman, Mats, and Dreyling, Martin

Published
2024

7. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE):a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Author

Dreyling, Martin, Doorduijn, Jeanette, Giné, Eva, Jerkeman, Mats, Walewski, Jan, Hutchings, Martin, Mey, Ulrich, Riise, Jon, Trneny, Marek, Vergote, Vibeke, Shpilberg, Ofer, Gomes da Silva, Maria, Leppä, Sirpa, Jiang, Linmiao, Stilgenbauer, Stephan, Kerkhoff, Andrea, Jachimowicz, Ron D., Celli, Melania, Hess, Georg, Arcaini, Luca, Visco, Carlo, van Meerten, Tom, Wirths, Stefan, Zinzani, Pier Luigi, Novak, Urban, Herhaus, Peter, Benedetti, Fabio, Sonnevi, Kristina, Hanoun, Christine, Hänel, Matthias, Dierlamm, Judith, Pott, Christiane, Klapper, Wolfram, Gözel, Döndü, Schmidt, Christian, Unterhalt, Michael, Ladetto, Marco, Hoster, Eva, Dreyling, Martin, Doorduijn, Jeanette, Giné, Eva, Jerkeman, Mats, Walewski, Jan, Hutchings, Martin, Mey, Ulrich, Riise, Jon, Trneny, Marek, Vergote, Vibeke, Shpilberg, Ofer, Gomes da Silva, Maria, Leppä, Sirpa, Jiang, Linmiao, Stilgenbauer, Stephan, Kerkhoff, Andrea, Jachimowicz, Ron D., Celli, Melania, Hess, Georg, Arcaini, Luca, Visco, Carlo, van Meerten, Tom, Wirths, Stefan, Zinzani, Pier Luigi, Novak, Urban, Herhaus, Peter, Benedetti, Fabio, Sonnevi, Kristina, Hanoun, Christine, Hänel, Matthias, Dierlamm, Judith, Pott, Christiane, Klapper, Wolfram, Gözel, Döndü, Schmidt, Christian, Unterhalt, Michael, Ladetto, Marco, and Hoster, Eva

Abstract

Background: Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT. Methods: The open-label, randomised, three-arm, parallel-group, superiority TRIANGLE trial was performed in 165 secondary or tertiary clinical centres in 13 European countries and Israel. Patients with previously untreated, stage II–IV mantle cell lymphoma, aged 18–65 years and suitable for ASCT were randomly assigned 1:1:1 to control group A or experimental groups A+I or I, stratified by study group and mantle cell lymphoma international prognostic index risk groups. Treatment in group A consisted of six alternating cycles of R-CHOP (intravenous rituximab 375 mg/m2 on day 0 or 1, intravenous cyclophosphamide 750 mg/m2 on day 1, intravenous doxorubicin 50 mg/m2 on day 1, intravenous vincristine 1·4 mg/m2 on day 1, and oral prednisone 100 mg on days 1–5) and R-DHAP (or R-DHAOx, intravenous rituximab 375 mg/m2 on day 0 or 1, intravenous or oral dexamethasone 40 mg on days 1–4, intravenous cytarabine 2 × 2 g/m2 for 3 h every 12 h on day 2, and intravenous cisplatin 100 mg/m2 over 24 h on day 1 or alternatively intravenous oxaliplatin 130 mg/m2 on day 1) followed by ASCT. In group A+I, ibrutinib (560 mg orally each day) was added on days 1–19 of R-CHOP cycles and as fixed-duration maintenance (560 mg orally each day for 2 years) after ASCT. In group I, ibrutinib was given the same way as in group A+I, but ASCT was omitted. Three pairwise o

Published
2024

8. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Author

Le Gouill, Steven, Długosz-Danecka, Monika, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Smith, Stephen D., Doorduijn, Jeanette K., Panizo, Carlos, Shah, Bijal D., Davies, Andrew J., Eek, Richard, Jacobsen, Eric, Kater, Arnon P., Robak, Tadeusz, Jain, Preetesh, Calvo, Roser, Tao, Lin, Wang, Michael, Le Gouill, Steven, Długosz-Danecka, Monika, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Smith, Stephen D., Doorduijn, Jeanette K., Panizo, Carlos, Shah, Bijal D., Davies, Andrew J., Eek, Richard, Jacobsen, Eric, Kater, Arnon P., Robak, Tadeusz, Jain, Preetesh, Calvo, Roser, Tao, Lin, and Wang, Michael

Published
2024

9. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma:Final results of the HOVON 105/ALLG NHL 24 study

Author

Bromberg, Jacoline E. C., Issa, Samar, van der Holt, Bronno, van der Meulen, Matthijs, Dirven, Linda, Minnema, Monique C., Seute, Tatjana, Durian, Marc, Cull, Gavin, van der Poel, Marjolein W. M., Stevens, Wendy B. C., Zijlstra, Josee M., Brandsma, Dieta, Nijland, Marcel, Mason, Kylie D., Beeker, Aart, Abrahamse-Testroote, Martine C. J., van den Bent, Martin J., de Jong, Daphne, Doorduijn, Jeanette K., Bromberg, Jacoline E. C., Issa, Samar, van der Holt, Bronno, van der Meulen, Matthijs, Dirven, Linda, Minnema, Monique C., Seute, Tatjana, Durian, Marc, Cull, Gavin, van der Poel, Marjolein W. M., Stevens, Wendy B. C., Zijlstra, Josee M., Brandsma, Dieta, Nijland, Marcel, Mason, Kylie D., Beeker, Aart, Abrahamse-Testroote, Martine C. J., van den Bent, Martin J., de Jong, Daphne, and Doorduijn, Jeanette K.

Abstract

Background. Studies on the efficacy of rituximab in primary CNS lymphoma (PCNSL) reported conflicting results. Our international randomized phase 3 study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide, and prednisolone (MBVP) in PCNSL was not efficacious in the short term. Here we present long-term results after a median follow-up of 82.3 months. Methods. One hundred and ninety-nine eligible newly diagnosed, nonimmunocompromised patients with PCNSL aged 18–70 years with WHO performance status 0–3 was randomized between treatment with MBVP chemotherapy with or without rituximab, followed by high-dose cytarabine consolidation in responding patients, and reduced-dose WBRT in patients aged ≤ 60 years. Event-free survival was the primary endpoint. Overall survival rate, neurocognitive functioning (NCF), and health-related quality of life (HRQoL) were additionally assessed, with the IPCG test battery, EORTC QLQ-C30 and QLQ-BN20 questionnaires, respectively. Results. For event-free survival, the hazard ratio was 0.85, 95% CI 0.61–1.18, P = .33. Overall survival rate at 5 years for MBVP and R-MBVP was 49% (39–59) and 53% (43–63) respectively. In total, 64 patients died in the MBVP arm and 55 in the R-MBVP arm, of which 69% were due to PCNSL. At the group level, all domains of NCF and HRQoL improved to a clinically relevant extent after treatment initiation, and remained stable thereafter up to 60 months of follow-up, except for motor speed which deteriorated between 24 and 60 months. Although fatigue improved initially, high levels persisted in the long term. Conclusions. Long-term follow-up confirms the lack of added value of rituximab in addition to MBVP and HD-cytarabine for PCNSL.

Published
2024

10. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final Results of the HOVON 105 / ALLG NHL 24 Study

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Neurologen, Bromberg, Jacoline E C, Issa, Samar, van der Holt, Bronno, van der Meulen, Matthijs, Dirven, Linda, Minnema, Monique C, Seute, Tatjana, Durian, Marc, Cull, Gavin, van der Poel, Marjolein W M, Stevens, Wendy B C, Zijlstra, Josee M, Brandsma, Dieta, Nijland, Marcel, Mason, Kylie D, Beeker, Aart, Abrahamse-Testroote, Martine C J, van den Bent, Martin J, de Jong, Daphne, Doorduijn, Jeanette K, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Neurologen, Bromberg, Jacoline E C, Issa, Samar, van der Holt, Bronno, van der Meulen, Matthijs, Dirven, Linda, Minnema, Monique C, Seute, Tatjana, Durian, Marc, Cull, Gavin, van der Poel, Marjolein W M, Stevens, Wendy B C, Zijlstra, Josee M, Brandsma, Dieta, Nijland, Marcel, Mason, Kylie D, Beeker, Aart, Abrahamse-Testroote, Martine C J, van den Bent, Martin J, de Jong, Daphne, and Doorduijn, Jeanette K

Published
2024

12. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up.

Author

Ferreri, Andreas J. M., Illerhaus, Gerald, Doorduijn, Jeanette K., Auer, Dorothee P., Bromberg, Jacoline E. C., Calimeri, Teresa, Cwynarski, Kate, Fox, Christopher P., Hoang‐Xuan, Khê, Malaise, Denis, Ponzoni, Maurilio, Schorb, Elisabeth, Soussain, Carole, Specht, Lena, Zucca, Emanuele, Buske, Christian, Jerkeman, Mats, and Dreyling, Martin

Published
2024
Full Text
View/download PDF

14. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

Author

Michot, Jean-Marie, Bouabdallah, Reda, Vitolo, Umberto, Doorduijn, Jeanette K, Salles, Gilles, Chiappella, Annalisa, Zinzani, Pier Luigi, Bijou, Fontanet, Kersten, Marie José, Sarmiento, Rafael, Mosulen, Silvia, Mendez, Cristina, Uttamsingh, Shailaja, Pourdehnad, Michael, Hege, Kristen, Chen, Tianlei, Klein, Christian, Hagner, Patrick R, Nikolova, Zariana, and Ribrag, Vincent

Published
2020
Full Text
View/download PDF

15. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Author

Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark-David

Published
2020
Full Text
View/download PDF

17. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.

Author

Bromberg, Jacoline E C, Issa, Samar, van der Holt, Bronno, van der Meulen, Matthijs, Dirven, Linda, Minnema, Monique C, Seute, Tatjana, Durian, Marc, Cull, Gavin, Poel, Marjolein W M van der, Stevens, Wendy B C, Zijlstra, Josee M, Brandsma, Dieta, Nijland, Marcel, Mason, Kylie D, Beeker, Aart, Abrahamse-Testroote, Martine C J, Bent, Martin J van den, Jong, Daphne de, and Doorduijn, Jeanette K

Published
2024
Full Text
View/download PDF

19. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

Author

Brown, Jennifer R, Hamadani, Mehdi, Hayslip, John, Janssens, Ann, Wagner-Johnston, Nina, Ottmann, Oliver, Arnason, Jon, Tilly, Hervé, Millenson, Michael, Offner, Fritz, Gabrail, Nashat Y, Ganguly, Siddhartha, Ailawadhi, Sikander, Kasar, Siddha, Kater, Arnon P, Doorduijn, Jeanette K, Gao, Lei, Lager, Joanne J, Wu, Bin, Egile, Coumaran, and Kersten, Marie José

Published
2018
Full Text
View/download PDF

21. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Author

Wang, Michael, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Casasnovas, Olivier, Smith, Stephen D, Damaj, Gandhi, Doorduijn, Jeanette, Lamy, Thierry, Morschhauser, Franck, Panizo, Carlos, Shah, Bijal, Davies, Andrew, Eek, Richard, Dupuis, Jehan, Jacobsen, Eric, Kater, Arnon P, Le Gouill, Steven, Oberic, Lucie, Robak, Taduesz, Covey, Todd, Dua, Richa, Hamdy, Ahmed, Huang, Xin, Izumi, Raquel, Patel, Priti, Rothbaum, Wayne, Slatter, J Greg, and Jurczak, Wojciech

Published
2018
Full Text
View/download PDF

22. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Author

Wang, Michael, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Casasnovas, Olivier, Smith, Stephen D., Damaj, Gandhi, Doorduijn, Jeanette K., Lamy, Thierry, Morschhauser, Franck, Panizo, Carlos, Shah, Bijal, Davies, Andrew, Eek, Richard, Dupuis, Jehan, Jacobsen, Eric, Kater, Arnon P., Le Gouill, Steven, Oberic, Lucie, Robak, Tadeusz, Jain, Preetesh, Frigault, Melanie M., Izumi, Raquel, Nguyen, Dorothy, Patel, Priti, Yin, Ming, and Długosz-Danecka, Monika

Published
2019
Full Text
View/download PDF

23. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Author

Spanjaart, Anne M., primary, Pennings, Elise R. A., additional, Mutsaers, Pim G. N. J., additional, van Dorp, Suzanne, additional, Jak, Margot, additional, van Doesum, Jaap A., additional, de Boer, Janneke W., additional, Niezink, Anne G. H., additional, Kos, Milan, additional, Vermaat, Joost S. P., additional, Sijs-Szabo, Aniko, additional, van der Poel, Marjolein W. M., additional, Nijhof, Inger S., additional, Kuipers, Maria T., additional, Chamuleau, Martine E. D., additional, Lugtenburg, Pieternella J., additional, Doorduijn, Jeanette K., additional, Serroukh, Yasmina I. M., additional, Minnema, Monique C., additional, van Meerten, Tom, additional, and Kersten, Marie José, additional

Published
2023
Full Text
View/download PDF

24. PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

Author

Linton, Kim, primary, Doorduijn, Jeanette, additional, El-Sharkawi, Dima, additional, Mous, Rogier, additional, Forconi, Francesco, additional, Lewis, David, additional, Gleeson, Mary, additional, Riches, John, additional, Mckay, Pam, additional, Stevens, Wendy, additional, Injac, Sarah G, additional, and Collins, Graham P, additional

Published
2023
Full Text
View/download PDF

25. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Author

Le Gouill, Steven, primary, Długosz-Danecka, Monika, additional, Rule, Simon, additional, Zinzani, Pier Luigi, additional, Goy, Andre, additional, Smith, Stephen D., additional, Doorduijn, Jeanette K., additional, Panizo, Carlos, additional, Shah, Bijal D., additional, Davies, Andrew J., additional, Eek, Richard, additional, Jacobsen, Eric, additional, Kater, Arnon P., additional, Robak, Tadeusz, additional, Jain, Preetesh, additional, Calvo, Roser, additional, Tao, Lin, additional, and Wang, Michael, additional

Published
2023
Full Text
View/download PDF

28. Clinical Impact of Polymerase Chain Reaction–based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study

Author

Huygens, Sammy, primary, Dunbar, Albert, additional, Buil, Jochem B, additional, Klaassen, Corné H W, additional, Verweij, Paul E, additional, van Dijk, Karin, additional, de Jonge, Nick, additional, Janssen, Jeroen J W M, additional, van der Velden, Walter J F M, additional, Biemond, Bart J, additional, Bart, Aldert, additional, Bruns, Anke H W, additional, Haas, Pieter-Jan A, additional, Demandt, Astrid M P, additional, Oudhuis, Guy, additional, von dem Borne, Peter, additional, van der Beek, Martha T, additional, Klein, Saskia K, additional, Godschalk, Peggy, additional, Span, Lambert F R, additional, Postma, Douwe F, additional, Kampinga, Greetje A, additional, Maertens, Johan, additional, Lagrou, Katrien, additional, Mercier, Toine, additional, Moors, Ine, additional, Boelens, Jerina, additional, Selleslag, Dominik, additional, Reynders, Marijke, additional, Zandijk, Willemien, additional, Doorduijn, Jeanette K, additional, Cornelissen, Jan J, additional, Schauwvlieghe, Alexander F A D, additional, and Rijnders, Bart J A, additional

Published
2023
Full Text
View/download PDF

29. The Dutch CAR-T Tumorboard Experience:Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Author

Spanjaart, Anne M., Pennings, Elise R.A., Mutsaers, Pim G.N.J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G.H., Kos, Milan, Vermaat, Joost S.P., Sijs-Szabo, Aniko, van der Poel, Marjolein W.M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I.M., Minnema, Monique C., van Meerten, Tom, Kersten, Marie José, Spanjaart, Anne M., Pennings, Elise R.A., Mutsaers, Pim G.N.J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G.H., Kos, Milan, Vermaat, Joost S.P., Sijs-Szabo, Aniko, van der Poel, Marjolein W.M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I.M., Minnema, Monique C., van Meerten, Tom, and Kersten, Marie José

Abstract

The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique nationwide infrastructure for referral, eligibility assessment and data collection. The aim of this study was to evaluate real-world outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including the thus-far underreported effects on health-related quality of life (HR-QoL). All patients with R/R LBCL after ≥2 lines of systemic therapy referred for axi-cel treatment between May 2020–May 2022 were included (N = 250). Of the 160 apheresed patients, 145 patients received an axi-cel infusion. The main reason for ineligibility was rapidly progressive disease. The outcomes are better or at least comparable to other studies (best overall response rate: 84% (complete response: 66%); 12-month progression-free-survival rate and overall survival rate: 48% and 62%, respectively). The 12-month NRM was 5%, mainly caused by infections. Clinically meaningful improvement in several HR-QoL domains was observed from Month 9 onwards. Expert-directed patient selection can support effective and sustainable application of CAR-T treatment. Matched comparisons between cohorts will help to understand the differences in outcomes across countries and select best practices. Despite the favorable results, for a considerable proportion of patients with R/R LBCL there still is an unmet medical need.

Published
2023

30. Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis:A Prospective Multicenter Study

Author

Huygens, S, Dunbar, Albert, Buil, Jochem B, Klaassen, Corné H W, Verweij, Paul E, van Dijk, Karin, de Jonge, Nick, Janssen, Jeroen J W M, van der Velden, Walter J F M, Biemond, Bart J, Bart, Aldert, Bruns, Anke H W, Haas, Pieter-Jan A, Demandt, Astrid M P, Oudhuis, Guy, von dem Borne, Peter, van der Beek, Martha T, Klein, Saskia K, Godschalk, Peggy, Span, Lambert F R, Postma, Douwe F, Kampinga, Greetje A, Maertens, Johan, Lagrou, Katrien, Mercier, Toine, Moors, Ine, Boelens, Jerina, Selleslag, Dominik, Reynders, Marijke, Zandijk, Willemien, Doorduijn, Jeanette K, Cornelissen, Jan J, Schauwvlieghe, Alexander F A D, Rijnders, Bart J A, Huygens, S, Dunbar, Albert, Buil, Jochem B, Klaassen, Corné H W, Verweij, Paul E, van Dijk, Karin, de Jonge, Nick, Janssen, Jeroen J W M, van der Velden, Walter J F M, Biemond, Bart J, Bart, Aldert, Bruns, Anke H W, Haas, Pieter-Jan A, Demandt, Astrid M P, Oudhuis, Guy, von dem Borne, Peter, van der Beek, Martha T, Klein, Saskia K, Godschalk, Peggy, Span, Lambert F R, Postma, Douwe F, Kampinga, Greetje A, Maertens, Johan, Lagrou, Katrien, Mercier, Toine, Moors, Ine, Boelens, Jerina, Selleslag, Dominik, Reynders, Marijke, Zandijk, Willemien, Doorduijn, Jeanette K, Cornelissen, Jan J, Schauwvlieghe, Alexander F A D, and Rijnders, Bart J A

Abstract

BACKGROUND: Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy. METHODS: In a prospective study, we evaluated the clinical value of the AsperGenius polymerase chain reaction (PCR) assay in hematology patients from 12 centers. This PCR assay detects the most frequent cyp51A mutations in A. fumigatus conferring azole resistance. Patients were included when a computed tomography scan showed a pulmonary infiltrate and bronchoalveolar fluid (BALf) sampling was performed. The primary end point was antifungal treatment failure in patients with azole-resistant IA. RESULTS: Of 323 patients enrolled, complete mycological and radiological information was available for 276 (94%), and probable IA was diagnosed in 99/276 (36%). Sufficient BALf for PCR testing was available for 293/323 (91%). Aspergillus DNA was detected in 116/293 (40%) and A. fumigatus DNA in 89/293 (30%). The resistance PCR was conclusive in 58/89 (65%) and resistance detected in 8/58 (14%). Two had a mixed azole-susceptible/azole-resistant infection. In the 6 remaining patients, treatment failure was observed in 1. Galactomannan positivity was associated with mortality (P = .004) while an isolated positive Aspergillus PCR was not (P = .83). CONCLUSIONS: Real-time PCR-based resistance testing may help to limit the clinical impact of triazole resistance. In contrast, the clinical impact of an isolated positive Aspergillus PCR on BALf seems limited. The interpretation of the EORTC/MSGERC PCR criterion for BALf may need further specification (eg, minimum cycle threshold value and/or PCR positive on >1 BALf sample).

Published
2023

31. Risk of second primary malignancies in patients with chronic lymphocytic leukemia:a population-based study in the Netherlands, 1989-2019

Author

van der Straten, Lina, Levin, Mark David, Dinnessen, Manette A.W., Visser, Otto, Posthuma, Eduardus F.M., Doorduijn, Jeanette K., Langerak, Anton W., Kater, Arnon P., Dinmohamed, Avinash G., van der Straten, Lina, Levin, Mark David, Dinnessen, Manette A.W., Visser, Otto, Posthuma, Eduardus F.M., Doorduijn, Jeanette K., Langerak, Anton W., Kater, Arnon P., and Dinmohamed, Avinash G.

Abstract

The longevity of patients with chronic lymphocytic leukemia (CLL) has improved progressively over the past decades, making it essential to understand long-term health outcomes, such as second primary malignancies (SPMs). Therefore, this nationwide, population-based study assessed the risk of SPM development in CLL patients diagnosed during 1989-2019 in the Netherlands compared to the expected number of malignancies in an age-, sex-, and period-matched group from the general Dutch population. In 24,815 CLL patients followed for 162,698.49 person-years, 4369 SPMs were diagnosed with a standardized incidence ratio (SIR) of 1.63 (95% confidence interval [CI] 1.59-1.68). This elevated risk was observed for solid (SIR, 1.67; 95% CI, 1.65-1.75) and hematological SPMs (SIR 1.42; 95% CI, 1.24-1.62). The highest risk for SPMs was noted beyond five years post-diagnosis (SIR, 1.70; 95% CI, 1.62-1.77), for male individuals (SIR, 1.70; 95% CI, 1.64-1.77), and patients aged 18-69 years (SIR, 1.92; 95% CI, 1.79-2.05). The risk of SPMs was higher in CLL patients who received anti-neoplastic therapy (SIR, 2.12; 95% CI, 1.96-2.28), as compared with those who did not (SIR, 1.58; 95% CI, 1.53-1.63). Routine surveillance activities and tailored interventions to counteract the increased morbidity and excess mortality associated with SPMs are essential for improving long-term outcomes in CLL patients.

Published
2023

32. Clinical impact of PCR-based Aspergillus and azole resistance detection in invasive aspergillosis. A prospective multicenter study

Author

Huygens, S, Dunbar, Albert, Buil, Jochem B, Klaassen, Corné H W, Verweij, Paul E, van Dijk, Karin, de Jonge, Nick, Janssen, Jeroen J W M, van der Velden, Walter J F M, Biemond, Bart J, Bart, Aldert, Bruns, Anke H W, Haas, Pieter-Jan A, Demandt, Astrid M P, Oudhuis, Guy, von dem Borne, Peter, van der Beek, Martha T, Klein, Saskia K, Godschalk, Peggy, Span, Lambert F R, Postma, Douwe F, Kampinga, Greetje A, Maertens, Johan, Lagrou, Katrien, Mercier, Toine, Moors, Ine, Boelens, Jerina, Selleslag, Dominik, Reynders, Marijke, Zandijk, Willemien, Doorduijn, Jeanette K, Cornelissen, Jan J, Schauwvlieghe, Alexander F A D, Rijnders, Bart J A, Internal Medicine, Medical Microbiology & Infectious Diseases, and Hematology

Abstract

BACKGROUND: Invasive aspergillosis(IA) by a triazole resistant Aspergillus fumigatus is associated with a high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy. METHODS: In a prospective study in the Netherlands and Belgium, we evaluated the clinical value of the multiplex AsperGenius®PCR in hematology patients from 12 centers. This PCR detects the most frequent cyp51A mutations in A. fumigatus conferring azole-resistance. Patients were included when a CT-scan showed a pulmonary infiltrate and bronchoalveolar lavage(BALf) sampling was performed. The primary endpoint was antifungal treatment failure in patients with azole-resistant IA. Patients with mixed azole-susceptible/resistant infections were excluded. RESULTS: Of 323 patients enrolled, complete mycological and radiological information was available in 276/323(94%) and probable IA diagnosed in 99/276(36%). Sufficient BALf for PCR testing was available in 293/323(91%). Aspergillus DNA was detected in 116/293(40%) and A.fumigatus DNA in 89/293(30%). The resistance PCR was conclusive in 58/89(65%) and resistance detected in 8/58(14%). Two had a mixed azole-susceptible/resistant infection. In the 6 remaining patients, treatment failure was observed in one. Galactomannan positivity was associated with higher mortality(p=0.004). In contrast, mortality of patients with an isolated positive Aspergillus PCR was comparable to those with a negative PCR(p=0.83). CONCLUSIONS: Real-time PCR-based resistance testing may help to limit the clinical impact of triazole resistance. In contrast, the clinical impact of an isolated positive Aspergillus PCR on BALf seems limited. The interpretation of the EORTC/MSGERC PCR criterion for BALf may need further specification (e.g. minimum Ct-value and/or PCR positive on >1 BALf sample).

Published
2023

35. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Author

Kersten, Marie José, primary, Dreyling, Martin, additional, Linton, Kim M., additional, Chitu, Dana, additional, Tonino, Sanne, additional, Kap, Marcel, additional, Liu, Roberto D, additional, Chamuleau, Martine E.D., additional, Visser, Hein P.J., additional, De Jongh, Eva, additional, Marijt, Erik WAF, additional, Leijs, Maria B.L., additional, Bilgin, Yavuz M., additional, Dürig, Jan, additional, McKay, Pamela, additional, Snijders, Tjeerd J.F., additional, Pettitt, Andrew, additional, Minnema, Monique C., additional, Prange-Krex, Gabriele, additional, Cuijpers, Maria, additional, Böhmer, Lara H., additional, Tick, Lidwine W., additional, Florschütz, Axel, additional, Silbermann, Matthijs, additional, Fijnheer, Rob, additional, Beeker, Aart, additional, Tolboom, Nelleke, additional, Mitea, Cristina, additional, Arens, Anne IJ, additional, Zwezerijnen, Gerben JC, additional, Klapper, Wolfram, additional, Coupland, Sarah E., additional, de Jong, Daphne, additional, Doorduijn, Jeanette K., additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

36. First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study

Author

Brink, Mirian, primary, van der Spek, Arie C., additional, de Heer, Koen, additional, Kersting, Sabina, additional, Tick, Lidwine W., additional, van der Straaten, Hanneke M., additional, Mous, Rogier, additional, Levin, Mark-David, additional, Raa, Doreen te, additional, van Gelder, Michel, additional, Doorduijn, Jeanette K., additional, Kater, Arnon P., additional, Huls, Gerwin, additional, and Bellido, Mar, additional

Published
2022
Full Text
View/download PDF

37. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Author

Dreyling, Martin, primary, Doorduijn, Jeanette K., additional, Gine, Eva, additional, Jerkeman, Mats, additional, Walewski, Jan, additional, Hutchings, Martin, additional, Mey, Ulrich, additional, Riise, Jon, additional, Trneny, Marek, additional, Vergote, Vibeke K.J., additional, Celli, Melania, additional, Shpilberg, Ofer, additional, Gomes da Silva, Maria, additional, Leppa, Sirpa, additional, Jiang, Linmiao, additional, Pott, Christiane, additional, Klapper, Wolfram, additional, Gözel, Döndü, additional, Schmidt, Christian, additional, Unterhalt, Michael, additional, Ladetto, Marco, additional, and Hoster, Eva, additional

Published
2022
Full Text
View/download PDF

38. Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Author

De Groot, Fleur A, primary, Doorduijn, Jeanette K., additional, Brink, Mirian, additional, De Groen, Ruben A.L., additional, De Haan, Lorraine M., additional, Noordenbos, Troy, additional, Sijs-Szabo, Aniko, additional, Lam, King Hong, additional, Diepstra, Arjan, additional, te Boome, Liane, additional, Terpstra, Valeska, additional, Böhmer, Lara H., additional, Zijlstra, Josée M., additional, Koens, Lianne, additional, Durian, Marc, additional, Oudshoorn, Mirjam A., additional, Veelken, Hendrik, additional, Van Der Poel, Marjolein W.M., additional, Abdul Hamid, Myrurgia, additional, Stevens, Wendy B.C., additional, van Rooij, J L.M, additional, Oostvogels, Rimke, additional, Neelis, Karen J., additional, van den Brand, Michiel, additional, Woei-a-Jin, F.J. Sherida H., additional, Tousseyn, Thomas, additional, Dierickx, Daan, additional, Jansen, Patty M., additional, Kersten, Marie Jose, additional, Bromberg, Jacoline, additional, Nijland, Marcel, additional, and Vermaat, Joost S.P., additional

Published
2022
Full Text
View/download PDF

40. CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

Author

Linton, Kim, Collins, Graham P., Forconi, Francesco, Shah, Nirav N., Dixit, Karan, Munir, Talha, Omer, Zulfa, El-Sharkawi, Dima, Doorduijn, Jeanette, Alencar, Alvaro, McKay, Pam, Riches, John, Gleeson, Mary, Lewis, David, Winter, Allison, Injac, Sarah, Shih, Ted, Nandakumar, Srinand, Tan, May, Cherala, Ganesh, Meredith, Erin, and Danilov, Alexey

Published
2024
Full Text
View/download PDF

41. Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

Author

Linton, Kim, Collins, Graham P., Forconi, Francesco, Shah, Nirav N., Dixit, Karan, Munir, Talha, Omer, Zulfa, El-Sharkawi, Dima, Doorduijn, Jeanette, Alencar, Alvaro, McKay, Pam, Riches, John, Gleeson, Mary, Lewis, David, Winter, Allison, Injac, Sarah, Shih, Ted, Nandakumar, Srinand, Tan, May, Cherala, Ganesh, Meredith, Erin, and Danilov, Alexey

Published
2024
Full Text
View/download PDF

44. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Author

Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)

Subjects
0301 basic medicine, Male, cd52 expression, Cancer Research, epstein-barr-virus, medicine.medical_treatment, CHOP, Gastroenterology, PROPHYLAXIS, 0302 clinical medicine, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Significant risk, Alemtuzumab, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Hematology, lymphoproliferative disorders, Hazard ratio, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, 3. Good health, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, Toxicity, PHASE-II, Female, medicine.drug, medicine.medical_specialty, prognostic-factors, Medication Adherence, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, non-hodgkin-lymphoma, Cyclophosphamide, Aged, Chemotherapy, therapy, business.industry, Lymphoma, T-Cell, Peripheral, DETUDE-DES-LYMPHOMES, medicine.disease, Survival Analysis, Peripheral T-cell lymphoma, 030104 developmental biology, Doxorubicin, Prednisone, business
Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Published
2021

45. The EHA Research Roadmap: Malignant Lymphoid Diseases.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, de Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie-Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H, Salles, Gilles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, de Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie-Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H, and Salles, Gilles

Published
2022

46. Conditional relative survival among patients with chronic lymphocytic leukaemia:A population-based study in the Netherlands

Author

van der Straten, Lina, Levin, Mark-David, Visser, Otto, Posthuma, Eduardus F M, Doorduijn, Jeanette K, Kater, Arnon P, Dinmohamed, Avinash G, van der Straten, Lina, Levin, Mark-David, Visser, Otto, Posthuma, Eduardus F M, Doorduijn, Jeanette K, Kater, Arnon P, and Dinmohamed, Avinash G

Abstract

Studies on conditional relative survival (CRS) in chronic lymphocytic leukaemia (CLL) have hitherto been lacking in the literature. We predicted up-to-date estimates of 5-year RS at diagnosis and for each additional year survived (i.e., CRS) up to 15 years post-diagnosis among CLL patients diagnosed during 2007-2020. We showed that 5-year CRS continues to decline gradually with each additional year survived in a contemporary era with access to novel-based agents, irrespective of age. This finding indicates that CLL patients continue to experience substantial excess mortality compared to an age- and sex-matched group from the general population.

Published
2022

47. Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia:a population-based study in the Netherlands, 1989–2018

Author

van der Straten, Lina, Maas, Carolien C.H.M., Levin, Mark David, Visser, Otto, Posthuma, Eduardus F.M., Doorduijn, Jeanette K., Langerak, Anton W., Kater, Arnon P., Dinmohamed, Avinash G., van der Straten, Lina, Maas, Carolien C.H.M., Levin, Mark David, Visser, Otto, Posthuma, Eduardus F.M., Doorduijn, Jeanette K., Langerak, Anton W., Kater, Arnon P., and Dinmohamed, Avinash G.

Published
2022

48. The EHA Research Roadmap:Malignant Lymphoid Diseases

Author

Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, De Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H., Salles, Gilles, Dreyling, Martin, André, Marc, Gökbuget, Nicola, Tilly, Hervé, Jerkeman, Mats, Gribben, John, Ferreri, Andrés, Morel, Pierre, Stilgenbauer, Stephan, Fox, Christopher, Maria Ribera, José, Zweegman, Sonja, Aurer, Igor, Bödör, Csaba, Burkhardt, Birgit, Buske, Christian, Dollores Caballero, Maria, Campo, Elias, Chapuy, Bjoern, Davies, Andrew, De Leval, Laurence, Doorduijn, Jeanette, Federico, Massimo, Gaulard, Philippe, Gay, Francesca, Ghia, Paolo, Grønbæk, Kirsten, Goldschmidt, Hartmut, Kersten, Marie Jose, Kiesewetter, Barbara, Landman-Parker, Judith, Le Gouill, Steven, Lenz, Georg, Leppä, Sirpa, Lopez-Guillermo, Armando, Macintyre, Elizabeth, Mantega, Maria Victoria Mateos, Moreau, Philippe, Moreno, Carol, Nadel, Bertrand, Okosun, Jessica, Owen, Roger, Pospisilova, Sarka, Pott, Christiane, Robak, Tadeusz, Spina, Michelle, Stamatopoulos, Kostas, Stary, Jan, Tarte, Karin, Tedeschi, Allessandra, Thieblemont, Catherine, Trappe, Ralf Ulrich, Trümper, Lorenz H., and Salles, Gilles

Abstract

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cellbased Immune Therapies; and Gene Therapy.

Published
2022

49. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstrom's Macroglobulinemia:Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

Author

Kersten, Marie José, Amaador, Karima, Minnema, Monique C., Vos, Josephine M.I., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E.D., Deeren, Dries, Tick, Lidwine W., Doorduijn, Jeanette K., Offner, Fritz, Böhmer, Lara H., Liu, Roberto D., Pals, Steven T., Dimopoulos, Meletios A., Kersten, Marie José, Amaador, Karima, Minnema, Monique C., Vos, Josephine M.I., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E.D., Deeren, Dries, Tick, Lidwine W., Doorduijn, Jeanette K., Offner, Fritz, Böhmer, Lara H., Liu, Roberto D., Pals, Steven T., and Dimopoulos, Meletios A.

Abstract

PURPOSE: Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor ixazomib combined with rituximab, in patients with relapsed WM. METHODS: resultsWe conducted a multicenter phase I/II trial with ixazomib, rituximab, and dexamethasone (IRD). Induction consisted of eight cycles IRD wherein rituximab was started in cycle 3, followed by rituximab maintenance. Phase I showed feasibility of 4 mg ixazomib. Primary end point for phase II was overall response rate (ORR [≥ minimal response]) after induction. RESULTS: A total of 59 patients were enrolled (median age, 69 years; range, 46-91 years). Median number of prior treatments was 2 (range, 1-7); 70% had an intermediate or high WM-IPSS (International Prognostic Scoring System for WM) score. After eight cycles, ORR was 71% (42 out of 59) (14% very good partial response [PR], 37% PR, and 20% minor response). Depth of response improved until month 12 (best ORR methods85% [50 out of 59]: 15% very good PR, 46% PR, and 24% minor response). Median duration of response was 36 months. The average hematocrit level increased significantly (0.33-0.38 L/L) after induction (P < .001). After two cycles of ixazomib and dexamethasone, immunoglobulin M levels decreased significantly (median 3,700-2,700 mg/dL, P < .0001). Median time to first response was 4 months. Median progression-free survival and overall survival were not reached. After median follow-up of 24 months (range, 7.4-54.3 months), progression-free survival and overall survival were 56% and 88%, respectively. Toxicity included mostly grade 2 or 3 cytopenias, grade 1 or 2 neurotoxicity, and grade 2 or 3 infections. No infusion-related reactions or immunoglobulin M flare occurred with use of subcutaneous rituximab. Quality of life imp

Published
2022

50. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

Author

Onderzoek NEU, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Kersten, Marie José, Amaador, Karima, Minnema, Monique C, Vos, Josephine M I, Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E D, Deeren, Dries, Tick, Lidwine W, Doorduijn, Jeanette K, Offner, Fritz, Böhmer, Lara H, Liu, Roberto D, Pals, Steven T, Dimopoulos, Meletios A, Onderzoek NEU, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Kersten, Marie José, Amaador, Karima, Minnema, Monique C, Vos, Josephine M I, Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E D, Deeren, Dries, Tick, Lidwine W, Doorduijn, Jeanette K, Offner, Fritz, Böhmer, Lara H, Liu, Roberto D, Pals, Steven T, and Dimopoulos, Meletios A

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results